Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSL | P07711 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 5/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23837230 | 0.89 | CTSS (0.60) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL17724519 | 0.89 | CTSS (0.60) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL1824416 | 0.86 | ATM (0.52) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL13168601 | 0.86 | ATM (0.69) | CTSSCTSLATMPPARGOPRK1 | |
| SCHEMBL16215928 | 0.86 | ATM (0.69) | CTSSCTSLATMPPARGOPRK1 | |
| SCHEMBL18435386 | 0.86 | CTSK (0.64) | CTSSCTSLATMCTSKALDH1A1 | |
| SCHEMBL2943917 | 0.85 | CTSS (0.67) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL2943915 | 0.85 | CTSS (0.67) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL1825249 | 0.84 | P2RX7 (0.55) | CTSSCTSLATMSYKBACE1 | |
| SCHEMBL304548 | 0.84 | CTSS (0.56) | CTSSCTSLATMCTSKOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CTSS 625/4885CTSL 869/4885ATM 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.